Lead Product(s) : Endostatin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Denovo Biopharma
Deal Size : Undisclosed
Deal Type : Acquisition
Denovo Biopharma Acquires a Novel Late-Stage Oncology Drug and Expands into Protein Therapeutics
Details :
Product Name : DB108
Product Type : Protein
Upfront Cash : Undisclosed
October 12, 2020
Lead Product(s) : Endostatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Denovo Biopharma
Deal Size : Undisclosed
Deal Type : Acquisition